Selective inhibition of cyclooxygenase‐2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood

Enflicoxib is approved for the treatment of pain and inflammation in canine osteoarthritis. The objective of this work was to assess the mechanistic basis of enflicoxib therapy investigating the COX inhibitory activity of enflicoxib (racemate), its enantiomers and its main metabolites using the cani...

Descripción completa

Detalles Bibliográficos
Autores principales: Solà, Josep, Menargues, Àngel, Homedes, Josep, Salichs, Marta, Álvarez, Inés, Romero, Luz, Vela, José Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306928/
https://www.ncbi.nlm.nih.gov/pubmed/35038171
http://dx.doi.org/10.1111/jvp.13042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306928/
https://www.ncbi.nlm.nih.gov/pubmed/35038171
http://dx.doi.org/10.1111/jvp.13042

Ejemplares similares